EUVIMEDEUVIMED entdecken
Open Access

Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent

Ivan S Chernov iD, Alexandra V Protas iD, Elena А Popova iD, Olga S Shemchuk iD, Natalia V Petukhova iD, Gulalek Babayeva iD, Valeria M Tretiakova iD, Vyacheslav E Bulakov iD, Pavel K Kozhukhov, Olga V Mikolaichuk iD, Il'ya V Kornyakov iD, Vadim S Pokrovsky iD und 2 weitere

Future Medicinal Chemistry · 19.05.2026 · 18 (10) · 1195-1210

DOI: 10.1080/17568919.2026.2658014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Medicinal Chemistry, online erschienen am 22.04.2026. Verfasst von Ivan S Chernov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pavlov First Saint-Petersburg State Medical University, St. Petersburg, Russia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Benzimidazoles, Drug Design, Triazines. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: State Program of the Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBenzimidazolesDrug DesignTriazinesAziridinesHumansAnimalsCell ProliferationMiceStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular Docking SimulationCell Line, TumorMice, NudePoly (ADP-Ribose) Polymerase-1Molecular Structure

Stichwörter der Autor:innen

1,3,5-triazineDNA alkylationPARP inhibitionaziridinebenzimidazolecomet assaycytotoxicitymolecular docking

Substanzen

Antineoplastic AgentsBenzimidazolesTriazinesAziridinesPoly (ADP-Ribose) Polymerase-1

Autor:innen und Institutionen

  • Pavlov First Saint-Petersburg State Medical University, St. Petersburg, Russia.
  • Institute of Experimental Medicine, St. Petersburg, Russia.
  • A.M. Granov Russian Research Centre for Radiology and Surgical Technologies, Saint Petersburg, Russia.
  • N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Peoples' Friendship University of Russia (RUDN University), Moscow, Russia.
  • Saint-Petersburg State University, St. Petersburg, Russia.

ORCID-Profile: Ivan S Chernov, Alexandra V Protas, Elena А Popova, Olga S Shemchuk, Natalia V Petukhova, Gulalek Babayeva, Valeria M Tretiakova, Vyacheslav E Bulakov, Olga V Mikolaichuk, Il'ya V Kornyakov, Vadim S Pokrovsky, Konstantin N Semenov, Vladimir V Sharoyko

Förderung

  • State Program of the Ministry of Health

Zitieren

APA

Chernov, I. S., Protas, A. V., Popova, E. А., Shemchuk, O. S., Petukhova, N. V., Babayeva, G., Tretiakova, V. M., Bulakov, V. E., Kozhukhov, P. K., Mikolaichuk, O. V., Kornyakov, I. V., Pokrovsky, V. S., Semenov, K. N., & Sharoyko, V. V. (2026). Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent. Future Medicinal Chemistry, 18(10), 1195-1210. https://doi.org/10.1080/17568919.2026.2658014

Vancouver

Chernov IS, Protas AV, Popova EА, Shemchuk OS, Petukhova NV, Babayeva G, et al. Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent. Future Medicinal Chemistry. 2026;18(10):1195-1210. doi:10.1080/17568919.2026.2658014

BibTeX
@article{Chernov2026,
  author = {Chernov, Ivan S and Protas, Alexandra V and Popova, Elena А and Shemchuk, Olga S and Petukhova, Natalia V and Babayeva, Gulalek and Tretiakova, Valeria M and Bulakov, Vyacheslav E and Kozhukhov, Pavel K and Mikolaichuk, Olga V and Kornyakov, Il'ya V and Pokrovsky, Vadim S and Semenov, Konstantin N and Sharoyko, Vladimir V},
  title = {Design, synthesis and biological evaluation of a 4,6-di(aziridin-1-yl)-1,3,5-triazine–benzimidazole hybrid as a potential dual-targeting anticancer agent},
  journal = {Future Medicinal Chemistry},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1195--1210},
  doi = {10.1080/17568919.2026.2658014}
}
Kostenlos starten →